22 unknown, 10 completed, 4 recruiting, 1 terminated. 15 Phase 4, 11 Not applicable, 5 Phase 3, 2 Phase 1, 2 Phase 2.
Follow PEG-rhG-CSF: new trials by email Literature Review of PEG-rhG-CSF trials Research Report on PEG-rhG-CSF
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma Etoposide, Cytarabine, PEG-rhG-CSF - Non-Hodgkin's Lymphoma, Hematopoietic Stem Cell Mobilization | Phase 3 | Recruiting | The Affiliated People's Hospital of Ningbo University | 99 | 2024-08-01 | 2025-12-04 |
| Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients Etoposide, Cytarabine, Pegfilgrastim - Multiple Myeloma, Hematopoietic Stem Cell Mobilization | Phase 3 | Recruiting | The Affiliated People's Hospital of Ningbo University | 99 | 2024-08-01 | 2024-07-25 |
| The Value of Peripheral Blood CD34+ Cell Dynamics Monitoring in Autologous Hematopoietic Stem Cell Transplant Mobilization PEG-rhG-CSF, G-CSF - Granulocyte Colony-Stimulating Factor | Early Phase 1 | Unknown | Zhongnan Hospital | 40 | 2024-02-01 | 2024-01-18 |
| the Efficacy and Safety of PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells in Lymphoma PEG-rhG-CSF, RhG-CSF - Lymphoma | Not applicable | Unknown | Ou Bai, MD/PHD | 144 | 2023-05-01 | 2023-04-28 |
| Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological Malignancies Etoposide, Cytarabine, PEG-rhG-CSF - Lymphoma, Multiple Myeloma | Not applicable | Unknown | The Affiliated People's Hospital of Ningbo University | 68 | 2022-11-01 | 2024-03-19 |
| Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malignancies Etoposide, Cytarabine, PEG-rhG-CSF - Hematological Malignancy | Not applicable | Unknown | The Affiliated People's Hospital of Ningbo University | 62 | 2022-09-01 | 2023-10-10 |
| A Clinical Study of Autologous Peripheral Blood Stem Cell Mobilization for PEG-G-CSF PEG-rhG-CSF - Granulocyte Colony-stimulating Factor, Stem Cell Mobilization | Phase 4 | Unknown | Ning Huang | 80 | 2022-06-30 | 2022-06-16 |
| A Study of PEG-rhG-CSF and rhG-CSF Used for Aplastic Anemia Granulocyte Deficiency PEG-rhG-CSF - Severe Aplastic Anemia | Not applicable | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 45 | 2022-06-05 | 2022-09-26 |
| Efficacy and Safety of PEG-rhG-CSF Injection for Neutrophil Reconstitution Following AHSCT in Lymphoma/Multiple Myeloma pegylated recombinant human granulocyte-colony stimulating factor - Lymphoma, Multiple Myeloma | Not applicable | Unknown | Yao Liu | 7 | 2022-04-22 | 2023-09-29 |
| Clinical Study on PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells PEG-rhG-CSF, RhG-CSF - Lymphoma | Phase 4 | Unknown | Chongqing University Cancer Hospital | 174 | 2022-03-01 | 2023-09-07 |
| G-CSF in Patients With Anti-PD-1-axis Therapy-resistant Recurrent or Metastatic Nasopharyngeal Carcinoma PEG-rhG-CSF - Granulocyte Colony-Stimulating Factor, PD-1 Inhibitor | Phase 1 | Unknown | Sun Yat-sen University | 25 | 2022-01-24 | 2022-02-03 |
| PEG-rhG-CSF Compared With rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell Transplantation PEG-rhG-CSF, rhG-CSF - Lymphoma | Not applicable | Unknown | Sun Yat-sen University | 80 | 2021-12-01 | 2021-12-14 |
| Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF MW05, PEG-rhG-CSF - Breast Cancer Female | Phase 2 / Phase 3 | Completed | Mabwell (Shanghai) Bioscience Co., Ltd. | 586 | 2020-09-21 | 2022-12-02 |
| Evaluate the Efficacy and Safety of PEG-rhG-CSF in Patients With Hemophagocytic Syndrome PEG-rhG-CSF, rhG-CSF - Hemophagocytic Syndrome | Not applicable | Unknown | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | 50 | 2020-08-01 | 2020-08-05 |
| Efficacy and Safety of Pegylated Recombinant Human Granulocyte Stimulating Factor in Secondary Prevention of Albumin Paclitaxel Combined With S-1 in the First-line Treatment of Advanced Pancreatic Cancer PEG-rhG-CSF - Advanced Pancreatic Cancer | Not applicable | Unknown | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | 20 | 2020-02-01 | 2020-01-23 |
| Efficacy and Safety of 4.5mg PEG-rhG-CSF Per Cycle in Preventing Neutropenia After Intensive Chemotherapy for Breast Cancer PEG-rhG-CSF - Breast Cancer, Neutropenia | Phase 4 | Completed | Peking University | 104 | 2019-08-01 | 2020-10-28 |
| Cost-Effectiveness Study of PEG-rhG-CSF in Prophylactic Treatment of Neutropenia After Chemotherapy in Lymphoma PEG-rhG-CSF, rhG-CSF - Lymphoma, Non-Hodgkin, Granulocyte Colony-Stimulating Factor | Phase 4 | Unknown | Ruijin Hospital | 250 | 2019-08-01 | 2019-09-10 |
| Evaluation of the Application of PEGylated Recombinant Human Granulocyte Stimulating Factor Injection (PEG-rhG-CSF) in Chemotherapy of Elderly Lymphoma Patients PEG-rhG-CSF - Elderly Lymphoma Patients | Not applicable | Unknown | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | 485 | 2019-02-22 | 2019-03-14 |
| Real World Study of PEG-rhG-CSF in Prevention of Chemotherapy-induced Neutropenia PEG-rhG-CSF - Chemotherapy-induced Neutropenia, Myelosuppression | Unknown | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | 1500 | 2019-02-13 | 2019-02-19 | |
| Evaluate the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia After Chemotherapy in Patients With Non-Hodgkin's Lymphoma PEG-rhG-CSF - Non Hodgkin's Lymphoma | Not applicable | Unknown | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | 104 | 2019-01-01 | 2020-08-04 |
Showing 20 of 37. Sign in to see all of them.
Lymphoma (8) · Breast Neoplasms (5) · Hematologic Neoplasms (3) · Lymphoma, Non-Hodgkin (3) · Multiple Myeloma (3) · Neutropenia (2) · Uterine Cervical Neoplasms (2) · Anemia, Aplastic (1) · Bone Neoplasms (1) · Esophageal Neoplasms (1) · Lymphohistiocytosis, Hemophagocytic (1) · Ovarian Neoplasms (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Recurrence (1) · Small Cell Lung Carcinoma (1)
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. (10) · Peking University (4) · The Affiliated People's Hospital of Ningbo University (4) · Chinese Academy of Medical Sciences (2) · Chongqing University Cancer Hospital (2) · Sun Yat-sen University (2) · Adello Biologics, LLC (1) · Air Force Military Medical University, China (1) · Anhui Provincial Hospital (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Mabwell (Shanghai) Bioscience Co., Ltd. (1) · Ning Huang (1) · Ou Bai, MD/PHD (1) · Ruijin Hospital (1) · Shandong University (1)
China (29) · United States (1)
Ying Lu (3) · Dongling Zou, M.D. (1) · Fuling Zhou (1) · Guanghai Dai (1) · Huiqiang Huang (1) · Huiqiang Huang, professor (1) · Jun Zhu (1) · Jun Zhu, MD (1) · Lihong Liu, PHD (1) · Liping Jing, Doctor (1) · Mei Shi, MD (1) · Ou Bai, doctor (1) · Peipei Ye (1) · Shusen Wang, Doctor (1) · Tao Ouyang, MD (1)
PMID 21233311, PMID 32928136, PMID 34078317, PMID 34240339, PMID 38497347, PMID 41510127